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Abstract: We report the development of a 3D OrbiSIMS instrument for label-free biomedical imaging.
It combines the high spatial resolution of secondary ion mass spectrometry (SIMS; under 200 nm for
inorganics and under 2 µm for biomolecules) with the high mass resolving power of an Orbitrap (>
240,000 at m/z 200). This allows exogenous and endogenous metabolites to be visualized in 3D with
sub-cellular resolution. We imaged the distribution of neurotransmitters—gamma-aminobutyric acid
(GABA), dopamine and serotonin with high spectroscopic confidence in the mouse hippocampus. We
also putatively annotated and mapped the sub-cellular localisation of 29 sulfoglycosphingolipids and
45 glycerophospholipids, and confirmed lipid identities with tandem mass spectrometry. We
demonstrated single-cell metabolomic profiling using rat alveolar macrophage cells incubated with
different concentrations of the drug amiodarone, observing that he up-regulation of phospholipid
species and cholesterol is correlated with the accumulation of amiodarone.
Aberrant regulation of biomolecules can lead to devastating pathologies. Therefore, methods able to
detect and identify metabolites with sub-cellular spatial resolution would be very valuable for studying
diseases as well as provide fundamental biological insights into metabolism heterogeneity at the
single-cell scale . The metabolites expressed by a cell are indicative of its physiological state at a given
time. The growing appreciation of the heterogeneous nature of metabolism motivates the need to
measure and understand metabolite and phenotype variations at a single-cell level.1-4 In particular, in
the pharmaceutical industry, there is a pressing need to improve drug efficacy and to reduce attrition
(failure)5, especially during late-stage drug development. Metabolic imaging with sub-cellular lateral
resolution would permit study of the effects of pharmaceuticals on cellular processes and identify
potential toxicological effects. A label-free method is needed that can identify where drugs go to
establish whether drug concentrations are sufficiently high in the right places to have a therapeutic
effect, or if the medicine is concentrating within organelles and causing toxicity.6
As highlighted recently there are numerous analytical challenges associated with measuring the
metabolome at the single-cell level.2 These include high dynamic fluctuations, chemical diversity
spanning a large dynamic range, the inability to amplify or tag metabolites, and the limited amount of
material in a single cell. Single-cell measurements require a sensitive, label-free method with high
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chemical specificity and dynamic range. Mass spectrometry imaging offers label-free imaging
capabilities and for certain analytes has sub-femtomole sensitivity.4
The quest for sub-cellular resolution metabolic imaging using mass spectrometry has led to significant
advances in instrumentation. Recent developments in high-resolution mass spectrometers, for
example the Orbitrap™ mass analyser7 with a mass resolving power in the range of 105-106, a mass
accuracy of < 1 ppm and MS/MS capability allow direct identification of metabolites from databases
such as LIPID MAPS.8 An elegant atmospheric pressure matrix assisted laser-desorption ionisation (AP-
MALDI) mass spectrometer (MS) source that combines an Orbitrap MS with a tightly focused laser
beam was recently reported9; the authors demonstrated sampling regions down to 1.44 µm in
diameter and a lateral resolution for tissue classification of 2.9 µm. The highest reported MALDI MS
spatial resolution was generated using a transmission geometry approach, allowing imaging of tissue
proteins with a laser spot diameter of 1 µm and a 2.5 µm step size.10
Secondary ion mass spectrometry (SIMS) is an increasingly popular method in the life-sciences11,12
since it provides high spatial resolution using a focused ion beam as the probe and image in 3D with
~5 nm depth resolution.13,14 There have been significant developments to improve its application for
biological studies, in particular to include MS/MS capability for identification. Such developments
include a quadrupole-orthogonal time-of-flight (ToF) spectrometer15, the J105 (IONOPTIKA, UK) using
a novel ToF-ToF design for continuous (non-pulsed) large cluster ion beams more suited to the
detection of large biomolecules12 and recently the addition of a linear ToF to a TRIFT (Physical
Electronics, MN, U.S.A.) spectrometer allowing parallel MS/MS imaging.16
Fourier Transform mass spectrometers17 are the most accurate for biomolecule identification since
they have the highest mass resolving power, mass accuracy and are capable of high-resolution MS/MS.
The first attempt to couple high spatial resolution SIMS with high mass resolving power spectrometry
combined a liquid metal ion gun with a Bruker Daltonics 7.0 T APEX II (Bruker, Germany) Fourier
Transform Ion Cyclotron Resonance (FT-ICR) MS18; the authors demonstrated the ability to acquire
spectra from a 50 μm x 50 μm pixel with 30,000 mass resolving power. Another group19 combined a
C60 primary ion beam with a FT-ICR instrument and achieved a spatial resolution of ~40 μm and 
100,000 resolving power when imaging cholesterol in a rat brain section. However, the signal-to-noise
ratio, even for the abundant cholesterol molecule, was low despite the large pixel size and very long
pixel acquisition times of 15 s.
The principal practical limitation of FT-ICR MS is that, although this instrument has the necessary mass
resolution and accuracy, it lacks the speed for capturing 3D or large 2D images; conversely axial-ToF
analysers have the speed, but lack the necessary accuracy to obtain chemical formulae. To overcome
this dichotomy, we have developed the 3D OrbiSIMS which uses a hybrid mass analyser design. The
3D OrbiSIMS combines the strengths of high-speed ToF imaging with the high mass resolving power,
high mass accuracy and MS/MS capability of the Q Exactive™ HF Orbitrap (Thermo Fisher Scientific,
Germany).20,21 To demonstrate the potential of the method, we examine the distribution of lipids and
neurotransmitters in brain tissue and amiodarone-induced lysosomal dysfunction in macrophages.
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RESULTS
The 3D OrbiSIMS instrument
We first describe the utility of the 3D OrbiSIMS from the perspective of a method for metabolic
imaging and then provide technical instrument details for interested readers. A schematic of the
instrument is given in Figure 1. The dual ion beam and dual analyser configuration (Fig. 1a) provides
ten operational modes for spectrometry, depth profiling, 2D and 3D imaging (Fig. 1b). For 2D imaging,
a typical approach is to use the ToF analyser with the bismuth liquid metal ion gun (Bi LMIG) to acquire
a fast (~30 minutes) survey image and identify a region of interest (mode 6). Subsequently, an image
can be acquired with the Orbitrap analyser (mode 7) giving high mass accuracy, high mass resolution
and MS/MS capability. In this mode, the argon gas cluster ion beam (GCIB) is used, which creates mass
spectra richer in intact biomolecules (e.g. lipids) and with significantly less fragmentation compared
with a Bi LMIG primary ion beam.22 Acquiring an image at the highest mass resolution with the
Orbitrap is slow (a 256 x 256 pixel image with a mass resolving power of 240,000 at m/z 200 would
take 9 hours). Consequently, the ToF analyser is needed.
SIMS enables high-resolution 3D molecular imaging and provides complementary information to other
MSI methods such as AP-MALDI. In SIMS, a 3D image is created from a stack of 2D images acquired at
different depths. The depth of the image is precisely controlled using an argon GCIB to gently sputter
away material. Our hybrid approach (mode 10) allows high-speed 3D imaging (Fig. 1c) using the Bi
LMIG with ToF acquisition for high spatial resolution images and high resolution mass spectra using
the Orbitrap analyser from the argon GCIB sputtering cycle between images.
An example of this new 3D imaging mode is demonstrated for a single alveolar macrophage cell
incubated in media with the drug, amiodarone, at a concentration of 6.25ug/mL for 72 hours (Figure
2). A sequence of 2D ToF MS images at successive 400 nm depths (Fig. 2a,b) are reconstructed (see
Methods) to produce a 3D image showing the distribution of amiodarone (Fig. 2c). The nucleus has
an unusual shape as found in our previous ToF-SIMS imaging study.23 The high spatial resolution (~300
nm) ToF MS data but with consequently poor mass resolution are complemented by the Orbitrap
spectra (Fig. 2d,e) allowing cell membrane (m/z 184.0732, C5H15NO4P+) and nuclear marker ions (m/z
156.8852, K2PO4+; m/z 156.9745, C2H8O2P3+) to be putatively annotated. A weaker interference ion is
also evident at m/z 156.9759 putatively annotated as C10H9N2+.
Instrument details
The 3D OrbiSIMS is based on the TOF.SIMS 5 platform (ION-TOF GmbH, Germany) which we hybridize
with a Q Exactive™HF Orbitrap (Thermo Fisher Scientific, Germany) MS (Fig. 1a). The Orbitrap analyser
provides high mass accuracy (sub-ppm), a high mass resolving power (from 15,000 at m/z 200 with an
acquisition rate >20 spectra/s up to 480,000 at m/z 200 with 1 spectrum/s), high sensitivity and a high
in-spectrum dynamic range (105 for ratio of total ion counts to noise). This is demonstrated by
resolving the fine isotope structure of the mass spectrum of crystal violet (Supplementary Fig. 1 and
Supplementary Table 1).
Both analysers share the same secondary ion extraction optics (2000 V potential) and consequently
analyse the same point on the sample using either the 30 keV Bi LMIG or a micro-focussed 5-20 keV
Arn GCIB with clusters in the range 1000 < n < 10,000 (see Methods). At the heart of the 3D OrbiSIMS
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is an electrostatic 90 degree deflector that selects either the ToF MS or by 90 degree deflection the
Orbitrap MS. The deflector can be pulsed with a frequency of up to 30 kHz. With the Orbitrap selected,
the secondary ions pass into the transfer system where they are decelerated to kinetic energies of
several tens of eV and are transferred via RF ion guides to the Q Exactive. To reduce the energy spread
of the secondary ions, the transfer system comprises a multi-stage collisional damping cell. This
replaces the standard ESI source and atmospheric pressure to vacuum interface of the Q Exactive HF.
All other components remain unaffected, allowing for acquisition of either MS or tandem MS/MS
experiments with high mass resolution and mass accuracy for structural-based identification
(Supplementary Fig. 2).
The micro-focused GCIB in combination with the Orbitrap MS enables simultaneous high-mass
resolving power and sub-cellular resolution. The resolution of the ion beam is measured (see
Methods) by imaging an electroformed mesh grid from the ion induced secondary electron image
(Supplementary Figs. 3,4). The secondary ion signal intensity is a further important parameter for the
achievable practical resolution. In the absence of a suitable biologically relevant lateral-resolution
reference device, we use two nuclei that exhibit clear chemical contrast to make x-axis and y-axis
resolution measurements using the summed intensity of 8 nuclear markers (see Methods). The
average resolution is determined to be 1.34 µm ± 0.24 µm (n=5) (Supplementary Fig. 5). It can be seen
from Supplementary Fig. 5 that the intensity of selected intact lipids is similar to the intensity for the
selected nuclear markers and therefore the spatial resolution will be similar. For inorganic materials,
the Bi LMIG can be operated in a quasi-continuous mode in combination with the Orbitrap MS to give
the highest simultaneous spatial resolution and mass resolving power. We demonstrate (see
Methods) a spatial resolution of 172 nm ± 61 nm (n=95) simultaneously with a mass resolving power
of 355 k for ZrO+ (Supplementary Fig. 6) using Bi32+.
The performance for 3D imaging and depth profiling is shown in more detail using a nanostructured
reference material (Supplementary Fig. 7). The m/z 564 profiles show sharp peaks at the Irganox 3114
delta-layers where the signal rises over four orders of magnitude. A depth resolution (see Methods)
of 11-13 nm is measured across all three modes. In modes 3 and 10, the secondary ions sputtered by
the GCIB are analyzed with the Orbitrap MS. This is an advantage over conventional dual-beam depth
profiling (mode 9) where the secondary ions sputtered by the GCIB, typically >95% of the sampled
volume, are not utilized.
Molecular pathology
The structure of the hippocampus directs neural connectivity and influences cognitive abilities.24-26 We
used the 3D OrbiSIMS to molecularly image the hippocampal region of a coronal section of mouse
brain at tissue scale, cellular scale and sub-cellular scale (Figure 3). The ion image (Fig. 3a) was aligned
and overlaid onto the optical images of adjacent H & E stained tissue section (Fig. 3b) to provide
complementary molecular pathology. The boundaries of anatomical regions of the brain (Fig. 3c) in
the ion image were defined using the histological features in the H & E section and the Allen Brain
Atlas.27
At the tissue scale, a fast large field of view ToF-MS ion image (mode 6, mass resolving power 5,000
at m/z 200, acquisition time 36 mins) shows the distribution of cholesterol (C27H45O, [M-H]-, m/z 385.3,
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green), the small molecular fragment [CNO]- (m/z 42.0, red) and lipid fragments (the summed
contribution of m/z 153.0 [C3H6PO5]-, m/z 255.2 [C16H31O2] - and m/z 281.2 [C18H33O2]-), blue) (Fig. 3a).
To demonstrate the improvement provided by the 3D OrbiSIMS, a section of the cornu ammonis 1
(CA1) region of the hippocampus was imaged with sub-cellular resolution (~2 μm) and high mass 
resolving power (240,000 at m/z 200, (mode 7)). The striated tissue layers in the hippocampus,
stratum radiatum (SR), pyramidal layer (SP), stratum oriens (SO), corpus callosum (CC), and the cortex
are chemically diverse. The cellular distribution of m/z 888.6245 putatively annotated as C24:1
Sulfatide [(3’-sulfo)Gal β-Cer(d18:1/24:1)] in the CC layer is mapped in green (Fig. 3d). An advantage
of argon GCIB is that there is little fragmentation of sulfatides as demonstrated for a reference sample
of the same lipid (Supplementary Fig. 8). For phospholipids, such as a phosphoethanolamine, however,
there is significantly more fragmentation (Supplementary Fig. 9). The high density of cell bodies in the
SP layer, stained purple/blue in the H & E correlated to the distribution of nuclear markers, adenine
and guanine. Their summed contributions are shown in red in the ion image. This contrasts with the
low density of neuronal cells in the SO and SR layers.
The instrument’s mass resolving power simultaneous with sub-cellular spatial resolution allows us to
probe the chemical composition of a single nucleus. The nucleus of a single interneuron in the SO
regions of the CA1 was selected and the mass spectra for all the pixels in the region of interest (ROI)
were summed (Fig. 3e). Purine based nucleobases adenine and guanine, as well as phosphorylated
species from the DNA, were detected.28 The high mass resolving power at low molecular weight and
high mass accuracy enabled putative annotation of the chemical formula of the signals.
These features also allowed the use of the LIPID MAPS database to putatively annotate 127 lipid
species including fatty acids, sterols, glycerophospholipids and sphingolipids (Supplementary Figs. 10,
11 and Supplementary Tables 2-8). The localization of 29 glycosphingolipid sulfatides were putatively
annotated and mapped. Both hydroxylated and non-hydroxylated sulfatides with chain lengths
ranging from 14 to 26 carbons with varying degrees of fatty acid saturation were identified. The
presence and assignment of C24(OH) sulfatide [(3’-sulfo)Gal β-Cer(d18:1/24:0(2OH))] was confirmed 
with in situ tandem MS (Fig. 4a). Sulfatide lipids are abundant in the extracellular membrane of myelin
and are responsible for the efficient conduction of electrical signals in the nervous system.29 These
molecules play an important role in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s
disease, and the ability to detect and identify sulfatides and other lipids at sub-cellular lateral
resolution will be beneficial to neuroscientists.
In many cases, the mass spectra, in the lipid mass range, showed multiple molecular ion signatures at
the same nominal mass (Fig. 4b) from a region of the hippocampus (Fig. 4c). As shown in the ion image
of the CA3 region (Fig. 4d) a peak at m/z 904.62012, putatively annotated as C24:1 (OH) sulfatide [(3’-
sulfo)Gal-Cer(d18:1/24:1(2OH))] with a mass accuracy of 1.1 ppm and a peak at m/z 904.65669 were
chemically and spatially resolved. A minimum mass resolving power of 25,000 is needed to resolve the
two peaks (Supplementary Fig. 12).
Mapping molecules in neuronal communication
Neurons employ signalling molecules, neurotransmitters, to communicate. These include glutamate,
gamma-aminobutyric acid (GABA), dopamine, norepinephrine, epinephrine, histamine, serotonin and
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acetylcholine. The 3D OrbiSIMS enables mapping of multiple neurotransmitter distributions in neural
tissue (Fig. 5a) in a single experiment. The putatively annotated neurotransmitters, GABA or isomer
([C4H8NO2]- at m/z 102.0560), dopamine (Fig. 5b) ([C8H10NO2]- at m/z 152.0718) and serotonin
([C10H11N2O]- at m/z 175.0877) were mapped in the CA3 (Fig. 5c,d) and CA1 (Fig. 5e) region of the
hippocampus. Tandem mass spectra of reference samples confirmed these peaks are observed in the
SIMS mass spectrum (Supplementary Fig. 13). The sub-ppm mass accuracy of these peaks gives
confidence in their assignment. In addition, we mapped the MS1-derived gas-phase fragment ions,
identified from tandem MS reference spectra of the neurotransmitters, and found their presence and
distribution to be consistent with the parent ions (Supplementary Fig. 13).
GABA was found to be most abundant in the SO region of the hippocampus and was below detection
in the SP regions in both the CA3 and CA1 ion images (Fig. 5). This finding is consistent with
observations made with immunocytochemistry and electrophysiology measurements.30 The
monoamine neurotransmitters, dopamine and serotonin, were homogeneously distributed
throughout the hippocampal formation. The ability to detect alterations in the balance of tonic-based
neurotransmitters with microscopic accuracy has the potential to elucidate the effects of neuroactive
substances, such as antidepressants31 or drugs such as cocaine which elevates dopamine levels in the
hippocampus.32
Single-cell metabolic profiling
We evaluated the metabolomic profile of individual cells treated with the drug amiodarone, a cationic
amphiphilic drug. At high doses and long-term usage, amiodarone [KEGG drug: D02910], a Vaughan-
Williams class III antiarrhythmic medication, is known to cause drug-induced phospholipidosis (PL).33-
35 PL is characterized by the prevalence of ‘foamy’ or phospholipid-laden macrophages. The exact
mechanism of phospholipidosis remains the subject of debate; a number of potential contributors
have been proposed. It is believed that the hydrophobic domain of amiodarone allows the molecule
to cross lipid membranes, including that of the lysosome. Inside the acidic environment of the
lysosome, amiodarone is hydrolyzed.36 The drug then accumulates in the lysosome, as this form is
unable to re-cross the membrane. The excess drug has then been proposed to inhibit the function of
the lysosomal phospholipase A2 (LPLA2, phospholipase A2 group XV)37, a protein responsible for
phospholipid catabolism leading to the observed phospholipid accumulation. Previously, it has been
shown that ToF SIMS is able to detect the [M+H]+ ion in a single rat alveolar macrophage cell23.
Recently, in a correlative NanoSIMS and electron microscopy study, the use of I- as a chemically specific
label for amiodarone and P- as a general lipid marker illustrated amiodarone internalisation in
lysosomes in the same cell type and a correlated increase in lipid.38
In order to evaluate the effects on the metabolic signature at the single-cell level, 3D OrbiSIMS
metabolic profiles (mode 2) were acquired for cultured macrophages incubated with various
concentrations of amiodarone (0, 1.56, 6.25 and 9.38 µg/mL). The average mass spectral signature
(Supplementary Fig. 14 and Supplementary Table 9) reveals variations in the lipid profiles among cells
in the treatment groups. Metabolic changes for the intact lipid at m/z 760.5848 and putatively
annotated as PC (34:1) [C42H83NO8P]+ (1.1 ppm) and cholesterol [M-H2O+H]+ at m/z 369.3514 (1.9 ppm)
for individual cells from four amiodarone treatment groups, control 0 µg/ml (n=8, blue), 1.56 µg/ml
(n=6, magenta), 6.25 µg/ml (n=3, green) and 9.38 µg/ml (n=7, red) are revealed in Fig. 6a,b. As
expected the amiodarone intensity per cell ([M+H]+ at m/z 646.0307 [C25H30I2NO3]+ (1.3 ppm)) varies
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approximately linearly with incubation concentration and also demonstrates a wide range in uptake
behaviour at the single-cell level (Fig. 6c). Amiodarone is confirmed from an MS/MS analysis (Fig. 6e
and Supplementary Fig. 15). The average PC (34:1) intensity increases over 10 fold and the cholesterol
[M-H2O+H]+ peak increases approximately exponentially with amiodarone concentration (Fig. 6b).
This finding is consistent with previous studies following amiodarone exposure.39 Whilst there is a high
degree of variability for individual cells in drug uptake and PC (34:1) upregulation we see that, when
intensities are shown in a correlation plot for individual cells, that there is a linear correlation
(Pearson’s correlation coefficient = 0.91895, R-square = 0.83739) (Fig. 6d). Such detail can only be
revealed by single-cell analysis.
Discussion
The 3D OrbiSIMS enables metabolic imaging with sub-cellular resolution. It combines the proven
power of the high-field Orbitrap for biological MS with the high-speed and high-spatial resolution 3D
imaging ToF-SIMS platform. We demonstrate a spatial resolution of under 200 nm (172 nm ± 61 nm)
(n=95) simultaneously with a mass resolving power of 355,000 for ZrO2 nanostructures using the Bi3
LMIG. The micro-focused argon GCIB permits imaging of intact sulfatide and phosphoinositol lipids
with a spatial resolution of under 2 µm simultaneously with a mass resolving power of >240 k at m/z
200. A resolution of under 1.5 µm (1.34 µm ± 0.24 µm) (n=5) is possible for a highly skilled operator.
Furthermore, a mass resolving power of >480,000 at m/z 200 can be achieved allowing the fine
structure of isotopic patterns to be resolved. The ability to resolve sub-cellular features including the
nucleus of an interneuron is also demonstrated.
To the best of our knowledge, this represents the highest reported simultaneous spatial and mass
resolutions. This provides complementary analysis to recently reported AP-MALDI imaging with 1.4
µm sampling (lateral resolution for tissue classification 2.9 µm).9 Indeed, imaging of biomolecules at
sub-cellular resolution requires a multi-technique strategy to bridge the length-scales and molecular-
scales with the NanoSIMS 50L (CAMECA, France) allowing 50 nm resolution of elemental or stable
isotope labels40-42 through to MALDI techniques that are able to image peptides and small proteins.9,10
The 3D OrbiSIMS is suited to metabolites and small molecules (<1000 Da) and fits between these
methods, enabling label-free analysis of lipid biochemistry and the role lipids play in disease pathology
at sub-cellular resolution. Sample preparation varies significantly across these methods with
NanoSIMS requiring special care to prevent delocalisation of molecules by solvents.38 AP-MALDI
requires the least sample preparation though similarly, care is required not to delocalise molecules
with matrix application. For 3D OrbiSIMS, care needs to be taken to freeze dry samples for vacuum
compatibility. The instrument is also configured for cryo analysis (see Methods).
The application of the 3D OrbiSIMS to the single-cell and its subcellular milieu will improve
understanding of the location in which a drug resides and the complex responses from on-target and
off-target engagement. The 3D OrbiSIMS provides rich multiplexed data sets, capturing hundreds of
compounds in a single measurement, with sub-cellular resolution. It has the potential to provide
critical insight on fundamental biological processes.
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Figure 1. The 3D OrbiSIMS spectrometer and modes of operation. A) Schematic of the 3D OrbiSIMS.
B) Table of methodologies and data types achievable given the ion beam and spectrometer selections.
C) Hierarchy summary of 3D imaging modalities (mode 8 -10).
Figure 2. 3D MS imaging using dual beam and dual spectrometer (mode 10) of single rat alveolar
macrophage cell incubated in media with the drug, amiodarone. A) Sequence of 30 keV Bi3+ (~300 nm
resolution) ToF-SIMS images of total ion counts at ~400 nm depths as the cell is sputtered away. B) As
A) colour overlay of phosphocholine marker (m/z 184), grey, nuclear marker (m/z 157), magenta and
amiodarone [M+H]+ (m/z 646), green C) 3D rendering of the cell with phosphocholine marker, (m/z
184, grey, opacity 0.40), nuclear marker (m/z 157, magenta) and amiodarone [M+H]+ (m/z 646), green.
D) High mass resolution spectrum from sputtered material using Orbitrap MS (blue) and low mass
resolution spectra obtained during imaging with the ToF MS (black) for phosphocholine marker. E) as
D) for nuclear marker. Results presented are from a single measurement.
Figure 3. 3D OrbiSIMS MS images of the hippocampal region of a coronal section of mouse brain at
tissue scale, cellular scale and sub-cellular scale. A) 30 keV Bi3+ (lateral resolution ~ 2 m, pixel size 2
m) ToF MS image (mode 6) of the hippocampus region of a coronal mouse brain section, cholesterol
(m/z 385.3, [C27H45O]-, green), the small molecule (m/z 42.0, [CNO]-, red) and glycerophospholipid
fragments (the summed contribution of m/z 153.0 [C3H6PO5]-, m/z 255.2 [C16H31O2]- and m/z 281.2
[C18H33O2]-), blue). B) The distribution of cholesterol and [CNO]- in the ion image are overlaid with the
histological features in the adjacent H & E stained brain section. C) Schematic outlining the anatomical
regions of the brain tissue. D) 20 keV Ar3000 (lateral resolution ~ 2 m, pixel size 1.95 m) Orbitrap MS
image (mode 7) of the CA1 region, the phosphoinositol headgroup (m/z 241.0121, [C6H10PO8]-, blue),
C24:1 Sulfatide [m/z 888.6245, (3’-sulfo)Gal β-Cer(d18:1/24:1)] ([C48H90NO11S]-, green) and adenine
(m/z 134.0473, [C5H4N5]-, red). Image is overlaid on the adjacent H & E stained brain section for
orientation. Boundaries between anatomical regions shown with white dashed lines. E) Detail of D)
for adenine (m/z 134.0473, [C5H4N5]- showing individual nuclei in the SO region with the background
subtracted mass spectrum of a single nuclei from a region of interest (black line), 15 pixels with
intensity > 2.7 x 103 threshold). Results presented are from a single measurement.
Figure 4. Identification of lipids and mapping their spatial distribution requires simultaneous high
spatial resolution and high mass resolution as well as tandem MS. A) 10 keV Ar3000 Orbitrap Tandem
MS (mode 2) of mass peak m/z 906.63 was used to identify the lipid species to be C24 (OH) Sulfatide
[(3’-sulfo)Gal β-Cer(d18:1/24:0(2OH))]. The chemical formula of each fragment peak assignment is 
provided. B) 20 keV Ar2500 (lateral resolution ~ 2 m, pixel size 1.95 m) Orbitrap mass spectrum (mode
7) showing a lipid molecule putatively annotated as C24:1 (OH) sulfatide [(3’-sulfo)Gal-
Cer(d18:1/24:1(2OH)), blue)] and a peak at m/z 904.65669. C) Optical image of H & E stained adjacent
tissue section showing the region of analysis (white dotted line) and D) Orbitrap MS images
(parameters as A) normalized to the total ion image of C24:1 (OH) sulfatide (blue), m/z 904.65669
(green) and m/z 124.0075 shown separately and as an overlay. Results presented are from a single
measurement.
Figure 5. Mapping of neurotransmitters in the hippocampus. A) The analysed regions in the CA1 and
CA3 regions of the hippocampus are shown on the H & E stained tissue section. B) Negative ion mass
spectrum (mode 7) between m/z 151.89 and m/z 152.10 showing a mass peak at m/z 152.0717 that
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is consistent with the deprotonated molecular ion of dopamine ([C8H10NO2]-) with mass accuracy
(0.257 ppm). C) Molecular maps in the CA3 region of, clockwise, GABA or isomer, dopamine and
serotonin using a gray scale overlaid with the sulfatide head-group ([C6H9O8S]-, green) and adenine
([C5H4N5]-, red). D) Single ion mapping of the same neurotransmitters in a polychromatic scale showing
the relative ion intensity in the anatomical regions. E) Similar ion images of the CA1 region (orientated
to A) show the distribution of GABA or isomer. All data acquired with 20 keV Ar3000 (lateral resolution
~ 2 m, pixel size 1.95 m) Orbitrap MS (mode 7). Results presented are from a single measurement.
Figure 6. Single-cell metabolomics for macrophages incubated with different concentrations of
amiodarone. Dose response curves for cells from four treatment groups, control 0 µg/ml (n=8, blue),
1.56 µg/ml (n=6, magenta), 6.25 µg/ml (n=3, green) and 9.38 µg/ml (n=7, red) incubation culture
concentrations for A) PC (34:1) at m/z 760.5848 [C42H83NO8P]+ (1.1 ppm), B) cholesterol [M-H2O+H]+
at m/z 369.3514 [C27H45]+ (1.9 ppm) and C) the protonated molecular ion of the drug compound,
amiodarone, at m/z 646.0307 [C25H30I2NO3]+ (1.3 ppm). For each plot the data points (spheres) are
overlaid on a box plot (25th quartile, median and 75th quartile) and the average (open circle) for each
treatment group is connected with dotted line. D) Scatter plot of amiodarone [M+H]+ intensity with
PC (34:1) [M+H]+ intensity for each cell. There is a positive linear correlation (Pearson’s correlation
coefficient = 0.91895). E) In situ tandem MS of amiodarone in a single cell. All data acquired with
20 keV Ar3000+ Orbitrap MS (mode 2).
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METHODS:
Sample preparation.
We prepared mouse brain tissue sections using the following procedure. All animal studies were
ethically reviewed and carried out in accordance with Animals (Scientific Procedures) Act 1986 and
the GSK Policy on the Care, Welfare and Treatment of Animals. Female CD-1 mice, typically 6-8 weeks
old, were sacrificed by Schedule 1 method. The brains were quickly extracted and frozen in dry ice.
The intact brain was stored at -80 °C until sectioning. Coronal tissue sections were cut with a thickness
of 10 μm using a Leica CM3050S cryostat (Leica, Germany) at -22 °C. The brain sections were thaw 
mounted on conductive indium tin oxide (ITO) glass slides (Bruker, Germany), and stored at -80 °C
until further use.
SIMS analysis and histological Haematoxylin and Eosin (H & E) staining were performed on the
adjacent tissue sections. The tissue was stained using a Leica ST5020 autostainer (Leica, Germany)
using standard H & E protocol at GlaxoSmithKline. The stained sections were cover slipped with a
xylene based mountant using a Leica CV5030 coverslipper (Leica, Germany). Optical images of the
H & E stained tissue sections were obtained with a Hamamatsu Nanozoomer 2.0 HT microscope with
20x magnification (Hamamatsu Photonics, Japan). Haematoxylin (Mayer) and Eosin (1% aqueous)
were obtained from Pioneer Research Chemicals Ltd (Essex, UK). The solvents, xylenes (ACS reagent
>98.5%, xylenes + ethylbenzene basis) and denatured ethanol (UK IDA Standard) were obtained from
Sigma Aldrich (Saint Louis, USA).
Reference samples of lipid and neurotransmitters were prepared as follows. C24:1 Mono-Sulfo
Galactosyl(ß) Ceramide (d18:1/24:1) (Avanti Polar Lipids, USA, CAS 1246355-69-0, purity >99%) was
drop deposited onto a clean silicon wafer from a 1:1 by volume methanol/chloroform solvent mixture.
Reference samples of gamma-aminobutyric acid (GABA) (Sigma-Aldrich, USA, CAS 56-12-2, purity
≥99%), dopamine (Sigma-Aldrich, USA, CAS 62-31-7) and serotonin ((Sigma-Aldrich, USA, CAS 50-67-9, 
purity ≥98%), were prepared similarly. A reference sample of 1,2-dilauroyl-sn-glycero-3-
phosphoethanolamine (Avanti Polar Lipids, USA, CAS 59752-57-7, purity >99%) was prepared by
pressing sample powder directly onto a previously cleaned silicon wafer using a clean metal spatula.
Single-cell studies used NR8383 cells (source is ATCC CRL-2192, Manassas, VA, USA), an immortalized
cell line derived from a lung macrophage (Sprague-Dawley rat). The cells have been tested for
mycoplasma within GlaxoSmithKline and are not listed in the database of commonly misidentified cell
lines. These were grown on indium tin oxide (ITO) glass slides (Bruker, Germany) with Ham's F-12
Nutrient Mixture media containing GlutaMax and Phenol Red (Gibco, USA) and 15 % dialyzed, heat-
inactivated fetal bovine serum (Gibco, USA). 5 mg/mL stock solutions of amiodarone hydrochloride
(Sigma-Aldrich, CAS 19774-82-4, purity 98 %) were prepared in 50:50 water/ MeOH. The stock
solutions were added to the growth media for a final media concentrations of 1.56 µg/mL, 6.25ug/mL
and 9.38ug/mL. The cells were incubated (5 % CO2 and 37 °C) in the drug containing media for 72 hrs.
Control cells were incubated alongside the dosed cells. To prepare the cells for analysis in the 3D
OrbiSIMS, the media was removed and the cells were washed three times with 150 mM ammonium
formate solution (Sigma-Aldrich, USA). This removes salts that cause unwanted signal suppression in
SIMS. The cells were frozen and dried under vacuum (Genevac, USA) and stored at -80 °C until analysis.
Before SIMS analysis, the samples were warmed to room temperature in a vacuum chamber. The cells
for Figure 2 were prepared using the same method, in the same laboratory by the same person but at
a later date.
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To demonstrate nanoscale resolution using the Bi LMIG simultaneously with high mass resolution
using the Orbitrap MS, a sample of Zirconium dioxide (ZrO2) nanostructures was prepared. ZrO2
nanoparticles were dispersed in aqueous solution and spotted onto a clean Al foil. During evaporation,
crystals formed that were heterogeneous in size and exhibiting nanoscale features. For evaluation of
the 3D imaging capability the NPL Organic Multilayer (OML) reference sample was used (NPL, UK). The
reference sample consists of layers of Irganox 1010 and Irganox 3114 deposited onto a Si substrate to
form four 1 nm thick layers of Irganox 3114 placed at depths of 50 nm, 100 nm, 200 nm, and 300 nm
in a 400 nm Irganox 1010 film.
3D OrbiSIMS instrumentation
The instrument uses a Q Exactive™ HF for Orbitrap MS. In the Orbitrap MS modes (Figure 1) a quasi-
continuous primary ion beam is used for secondary ion generation without affecting the mass
resolution. This is due to the intermediate trapping capabilities of the Orbitrap for the secondary ion
beam. Tandem MS, also known as MS/MS, operates in the same way as a Q Exactive™ HF. In this
mode, the quadrupole mass filter isolates the precursor ions and the ions are fragmented in the
higher-energy collisional dissociation (HCD) collision cell (with nitrogen gas, 0-100 eV collision energy).
The fragment ions are transferred to the C-trap and orthogonally injected into the Orbitrap cell to
produce MS/MS spectra with full mass resolution and mass accuracy. The MS/MS capability and the
high-mass resolving power of the Orbitrap analysis improve signal to noise and the ability to detect
low-abundance ions that may be obscured by nearby ions of higher intensity.
In ToF MS modes short (< ns) primary ion pulses generate secondary ions which are accelerated from
the sample surface into the ToF analyser. In all SIMS experiments (both ToF MS and Orbitrap MS) an
extraction potential of 2000 V is used (opposite polarity to the secondary ion). The measurement
principle of the ToF requires either short primary ion pulses or in case longer primary ion pulses (< 200
ns) are applied a pulsed and delayed extraction of the mass analyser extraction electrode to obtain
good mass resolution. Due to the very different ion detection systems (ToF MS uses single ion counting
and Orbitrap MS uses image current detection and Fourier Transformation) the numerical values of
the resulting signal intensities cannot be compared one-to-one. For the Orbitrap MS results a
conversion factor needs to be determined in order to calculate the number of ions detected.
The 3D OrbiSIMS is equipped with a newly developed 30 keV bismuth cluster Bi LMIG (Bi Nanoprobe,
ION-TOF GmbH) with a lateral resolution of < 200 nm (Supplementary Fig. 6). The ion gun is able to
operate with selected cluster species (e.g Bi3+) in a quasi-continuous (DC) mode using a Wien filter. In
combination with the ToF mass analyser usually 0.6 ns long ion pulses are achieved if bunching is
applied. Longer pulse durations of 1.5 -150 ns can be obtained in un-bunched operation. In addition,
a new 20 keV argon GCIB provides a focused beam of Ar clusters with <2 μm lateral resolution imaging 
(Supplementary Fig. 5). For the GCIB the size of the virtual source is larger compared to the Bi LMIG,
rendering it technically more demanding to get to a small focal spot size. In order to improve the focal
spot size of the gas cluster ion source the ion optical demagnification of the ion column was increased
by optimization of the electrostatic lenses. Additionally, an aperture was introduced in order to block
larger beam angles, thereby reducing aberration effects. The loss of beam current is more than
compensated by operating the ion beam in a quasi-continuous mode for combination with the
Orbitrap MS. By taking these measures it was possible to decrease the spot size to below 2 µm with a
current of more than 30 pA and Orbitrap MS images with a resolution of <2 μm could be achieved. 
The 3D OrbiSIMS can accommodate a large analysis area (up to the size of the sample holder, 100 mm
x 70 mm). Its field of view and lateral resolution is ultimately limited by the acquisition time and the
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size of the data file. Details of the GCIB with Orbitrap MS imaging mode 7 are provided in the
Supplementary Protocol.43 The instrument has cryogenic sample cooling in both the analysis and
preparation chamber (sample temperature < -130 oC (143 K)) with a Leica VCT 500 (Leica, Germany)
sample transfer system compatible with cryo-SEM and cryo-TEM instruments.
Pathways to reproducibility
To improve reproducibility between operators, we use mouse brain tissue samples from the same
batch for training purposes and validation of the instrument performance. Images with the same
spatial resolution and mass resolving power can be reproduced. To help with reproducibility, we
include in the Supplementary Protocol43 an author outside of this study. Reproducibility between
instruments is not yet tested as this is currently the only instrument.
3D OrbiSIMS experimental methods
Mass calibration of the Q Exactive instrument was performed once a day using silver cluster ions. Mass
calibration of the ToF was performed using the same ions. For the 3D single-cell image (mode 10) in
Figure 2 the high lateral resolution images were obtained with 30 keV Bi3+ LMIG (approximately 300
nm resolution) from an analysis area of 100 µm x 100 µm using the ToF MS. These images are
interleaved by Orbitrap MS acquired during the 20 keV Ar3000+ GCIB sputtering cycle from the same
field of view, but with an additional sputter border of 20 µm width to avoid edge effects. 50 scans
were accumulated in the ToF images corresponding to a total primary ion dose of 3.3 x 1012 ions/cm².
The total GCIB sputtering dose was 1.1 x 1015 ions/cm². The cell height is estimated from AFM
topographic images, Asylum MFP-3D (Asylum Research, USA), of 4 cells from the same sample post
exposure to the 3D OrbiSIMS vacuum.  The average cell height is 2.04 μm ± 0.23 μm (μ ± 1σ) n = 4
(2.04 μm, 2.23 μm, 2.18 μm, 1.71 μm). In Figure 3-5, the coronal tissue section was imaged with a
focused 20 keV Ar3000+ ion source (in Fig. 4, 20 keV Ar2500+) with the Orbitrap MS (mode 7). A step-by-
step protocol for label-free imaging of biomolecules, including lipids and neurotransmitters, in murine
brain sections using the 3D OrbiSIMS is provided in the Supplementary Protocol.43 An ion image
containing 256 x 256 pixels was acquired over an area of 500 μm x 500 μm [pixel size = 1.95 μm x 1.95 
μm].  Approximately, 2300 shots at 240 μs per cycle were accumulated in the C-trap per pixel. The 
Orbitrap analyser was operated in negative and positive ion mode at the 240,000 at m/z 200 mass
resolution setting [512 ms transient time]. Mass spectra information was collected for a mass range
from 60 to 1000 Da. The total ion dose was 2.0 x 1015 ions/cm2. The total ion image acquisition time
was approximately 10 hrs. Fast imaging survey image of the hippocampus formation was obtained
with a pulsed 30 keV Bi3+ ion beam and the ToF mass analyser (mode 6). Stage and ion beam rastering
were used to image the 3.5 mm x 2.3 mm analysis area [pixel size = 2 μm, ion images down binned to 
8 μm by combining adjacent pixels]. The fast ToF MS image was acquired in negative ion mode and 
took approximately 36 mins. The total ion dose was 4.2 x 1010 ions /cm2. The mass resolving power of
the image was approximately 5000 at m/z 200. In Fig. 3d, the spectrum is for 15 pixels defined by an
intensity threshold of > 2.7 x 103 with a background spectrum subtracted. The background spectrum
was obtained by summing 15 pixels in the SO region of the ion image where the adenine signal is
absent. The tandem MS spectrum in Fig. 4a was obtained using a 10 keV argon cluster beam. The
collisional cell energy was set to 65 V. The spectra were accumulated for 60 s as the ion beam rastered
in a random pattern in the CC region of the brain section. The tandem MS spectrum of a cholesterol
(Supplementary Fig. 2) at m/z 369.3509 was acquired with a collision energy of 30 eV from the corpus
callosum of a coronal mouse brain section, where it was found in abundance. The mass spectrum was
taken at full mass resolving power and summed over 60 seconds.
We acquired metabolic profiles of amiodarone dosed cells (Fig. 6) using a 20 keV Ar3000+ ion beam and
the Orbitrap MS (Mode 2).  Spectra were summed across an analysis area of 20 μm x 20 μm until the 
entire cell was consumed. The Orbitrap analyser was operated in positive ion mode at the 240,000 at
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m/z 200 mass resolution setting [512 ms transient time]. Mass spectra information was collected for
a mass range from 60 to 1000 Da. The total ion dose ranged from 1.3 x 1014 to 7.8 x 1014 ions/cm2.
To demonstrate the capability for depth profiling and 3D imaging we obtained negative ion data from
the NPL organic multilayer reference material for three modes: mode 3 (single beam, 5 keV Ar2000+,
Orbitrap MS); mode 9 (analysis with 30 keV Bi3 and ToF MS, sputtering 5 keV Ar2000+) and mode 10 (5
keV Ar2000+ sputtering and Orbitrap MS analysis and 30 keV Bi3 with ToF MS imaging). For all three
modes, a 5 keV Ar2000+ beam with a current of 41 pA was used for sputtering a 250 μm × 250 μm region 
of the sample. The beam is defocussed to a spot size of 20 μm.  Electrons with an energy of 21 eV and 
a current of 10 μA were used for charge compensation. In operational modes 3 and 10, secondary ions 
sputtered by the Ar2000+ beam from the central 130 μm × 130 μm of the crater were analysed using 
the Orbitrap spectrometer. In the dual beam modes, modes 9 and 10, secondary ion images with 128
x 128 pixels were obtained from the central 130 μm × 130 μm of the crater using a pulsed 30 keV Bi3+
with a beam current of 0.05 pA, and using the ToF analyser. These dual beam experiments were
carried out in the non-interlaced mode. In mode 9, the sample was sputtered using the Ar2000+ beam
for 2.0 s per cycle and imaged using the Bi3+ beam for 3.28 s. The ion dose ratio was 0.7% (Bi3+-to-
Ar2000+). In mode 10, the sample was sputtered for 7.5 s per cycle, giving a dose ratio of 0.2%. The
depth resolution is measured as the full width at half maximum of the m/z 564 delta layer peaks.
Data analysis
The 3D OrbiSIMS was controlled by software provided by SurfaceLab Version 6.7 (ION-TOF, Germany),
which utilized the Thermo Fisher provided application programming interface (API) for both control
of the Orbitrap MS portion of the instrument as well as online retrieval of the data. Both ToF-SIMS
and Orbitrap MS image analyses were performed using SurfaceLab Version 6.7 (ION-TOF, Germany),
OriginPro 2016 and MATLAB 2016a. Chemical structures were drawn in ChemDraw 14.0.
All Orbitrap MS images, depth profiles and linescans were created with a tolerance between ±2 and
±15 ppm, depending on the width of the signal peak, which increases proportional to the square root
of its mass. This is the reciprocal of the resolving power at a given mass x 106. The resolving power is
plotted in Supplementary Fig. 1b.
In Figure 2, the ToF-SIMS ion images for m/z 184, 157 and 646 were smoothed with a smoothing filter
(average 1, ION-TOF SurfaceLab). 3D renderings were constructed using an iso surface visualisation
for m/z 184 with a 7.2% iso value, 40% opacity, xy binning of 16 pixels and z binning of 4 scans. For the
nuclear marker, m/z 157, and amiodarone [M+H]+, m/z 646, a so-called volume visualization using a
threshold at 15% with the same binning. SurfaceLab Version 6.7 (ION-TOF, Germany) was used. The
3D image was created after the z position of the voxels was adjusted to take the initial sample
topography into account, using the assumption that the indium tin oxide substrate is a uniform flat
plane.44
Statistical analysis
Samples were not randomised. The biological samples are included to demonstrate the new
capabilities with the OrbiSIMS method rather than specific and comprehensive biological studies. The
investigators were not blinded to group allocation.
The resolution of the GCIB beam was measured by imaging an electroformed mesh grid from the ion
induced secondary electron image (Supplementary Fig. 3a). To achieve a reliable measurement the
lateral resolution was measured from 246 line scans across the edge of the grid in different locations
spread over 4.7 μm for both the x-axis and y-axis (Supplementary Fig. 3b,c). The FWHM of the ion 
beam profile (lateral resolution) is determined from the distance interval between the 88% to 12%
intensities of an error function fit to the linescan across the edge. The resolution measurements are
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fitted to a normal distribution with a mean and standard deviation of 1.72 μm ± 0.24 μm (n=246)
across the x-axis and 1.04 μm ± 0.16 μm (n=246) across the y-axis (Supplementary Fig. 3d). The
difference in the x-axis and y-axis FWHM lateral resolution measurements is due to the 45o angle of
incidence along the x-axis (Supplementary Fig. 3). The same procedure was conducted with the
secondary ion extraction potential on (needed for ion detection) and resolution degrades with the ion
extraction optics (Supplementary Fig. 4). The average FWHM lateral resolution was 2.49 μm ± 0.36 μm 
(μ ± 1σ) (n=243, grey bars) across the x-axis and 1.84 μm ± 0.36 μm (μ ± 1σ) (n=254, red bars) across
the y-axis. For a practical measurement of the resolution in tissue imaging 5 measurements are made
from the intensity line scan of summed intensity of nuclear markers [C4N3]- at m/z 90.0095 (2.8 ppm),
[CN2O2P]- at m/z 102.9702 (0.6 ppm), [C4H2N4]- at m/z 106.0285 (0.3 ppm), [C4H3N4]- at m/z 107.0207
(0.2 ppm), [C5HN4]- at m/z 117.0207 (0.2 ppm), [C5H3N4]- at m/z 119.0363 (0.3 ppm), [C5HN4O]- at m/z
133.0156 (0.1 ppm) and [C5H4N5]- at m/z 134.0472 (-0.1 ppm). The mean and standard deviation
values are 1.34 µm ± 0.24 µm (n=5).
The spatial resolution for the 30 kV Bi32+ LMIG was determined using the ZrO2 nanostructures shown
in the total ion image (Supplementary Fig. 6a) and the ZrO+ image (Supplementary Fig. 6b). We
acquired a high resolution secondary electron image (Supplementary Fig. 6c) and ion image
(Supplementary Fig. 6d) from a 20 µm x 20 µm region with a pixel size of 78 nm. As previously, 95 y-
axis line scans of the total ion intensity across the edge of the crystal were acquired (Supplementary
Fig. 6e). Measurements were made over a length of 1.5 µm. A normal distribution is fitted to the
population to give the mean and standard deviation of 172 nm ± 61 nm (μ ± 1σ) (n=95). The bismuth
ion gun was operated at 60 μs per cycle and 1800 shots per pixel. The secondary ions were collected 
in the C-trap for 500 ms before being injected into the Orbitrap analyser. The trap was operated in
positive ion mode, at the 240,000 at m/z 200 mass resolution setting. The total ion dose was 4.28 x
1016 ions/cm2. The total ion image acquisition time was approximately 9 hrs.
The single-cell drug accumulation and lipid upregulation (Fig. 6d) correlation calculations were
performed in OriginPro software (2015; OriginLab, MA, USA). The correlation test was performed
using a Pearson's (2-tailed) correlation test at the 95% confidence level.
Data availability
The data that support the findings of this study are available in figshare with the identifier
10.6084/m9.figshare.5459680.45 We provide the Orbitrap data in the mzML format for spectra and
the centroided ImzML format for images. The ToF image in Figure 2 is in the GRD data (TOF-SIMS
generic raw data) format. Data may be opened using Spectral Analysis software46 available from
Github: https://github.com/AlanRace/SpectralAnalysis.
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